We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 43

Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 26 2010

In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness

Novopharm Limited v. Eli Lilly and Company (2010 FC 915)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

An impeachment action was brought by Novopharm in respect of a patent for STRATTERA alleging obviousness, anticipation, utility and improper selection

Methods of medical treatment claims issues in Canada, US and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

Apotex v Sanofi, case management directions on the late disclosure of documents or information

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

Prior to a case management conference within a streamlined case, the Prothonotary ordered the parties to make submissions at the conference on the question of whether a date should be set after which the parties required either consent of the other party or leave of the Court to serve a supplementary affidavit of documents or a corrected or completed information in answer to a discovery question

Novopharm v Pfizer, motion for interim relief pending appeal, pregabalin, October 5, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

See the earlier decisions in this case in the May 2010 and July 2010 editions of this newsletter

AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing

Merck v Apotex, PMNOC proceedings, dorzolamide and timolol, October 22, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Merck’s patent in this case (the ‘965 patent) covered the co-administration and co-formulation of dorzolamide and timolol (which was sold as COSOPT

Merck v Apotex, PMNOC proceedings, dorzolamide, October 22, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

This proceeding for an order of prohibition was a companion case to the case described below

Novopharm v. Eli Lilly, appeals of decisions of the Case Management Prothonotary

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

Eli Lilly appealed two interlocutory decisions made by the Case Management Prothonotary

Hospira v Eli Lilly, appeal of order for further and better production of documents, gemcitabine, October 26, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Eli Lilly alleged that gemcitabine made in China and imported into Canada by Hospira infringes Eli Lilly's patent for an intermediate process step in the manufacture of gemcitabine